vaccines - versus CoronaVac (SinoVac) - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

safety endpoints 00

intracranial hemorrhage 1.03 [0.02, 52.46]< 10%1 study (1/-)49.3 %NAnot evaluable non important-
ischemic stroke 1.03 [0.02, 52.46]< 10%1 study (1/-)49.3 %NAnot evaluable non important-
Myocardial infarction 1.03 [0.02, 52.46]< 10%1 study (1/-)49.3 %NAnot evaluable non important-
pulmonary embolism 1.03 [0.02, 52.46]< 10%1 study (1/-)49.3 %NAnot evaluable non important-
venous thromboembolism 1.03 [0.02, 52.46]< 10%1 study (1/-)49.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.